PRMT5 and chronic myelogenous leukemia, BCR-ABL1 positive: Consequently, in mouse models of CML (by transplantation of BCR-ABL1-transduced bone marrow cells) PRMT5 knock-down or pharmacological inhibition increases mice survival [137].